NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

IOVA

Iovance Biotherapeutics Inc

May 16 • 04:00PM ET

1.66

Dollar change -0.10
Percentage change -5.68	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN FATE TVRD PRTA CRSP EDIT SGMO QURE ADAP NTLA

| Held by: VTI VB VBR VXF IWM XBI VTWO IWO IBB VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.23	Insider Own	19.01%	Shs Outstand	333.93M	Perf Week	-5.14%
Market Cap	554.33M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	0.04%	Shs Float	270.44M	Perf Month	-45.93%
Income	-375.36M	PEG	-	EPS next Q	-0.29	Inst Own	63.48%	Short Float	27.57%	Perf Quarter	-70.20%
Sales	212.68M	P/S	2.61	EPS this Y	10.19%	Inst Trans	1.43%	Short Ratio	5.75	Perf Half Y	-82.87%
Book/sh	2.30	P/B	0.72	EPS next Y	34.83%	ROA	-40.88%	Short Interest	74.57M	Perf Year	-84.51%
Cash/sh	1.08	P/C	1.54	EPS next 5Y	47.62%	ROE	-51.85%	52W Range	1.65 - 12.51	Perf YTD	-77.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.17%	ROI	-46.22%	52W High	-86.73%	Beta	0.85
Dividend TTM	-	Quick Ratio	3.64	Sales past 5Y	2739.80%	Gross Margin	11.01%	52W Low	0.61%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	4.18	EPS Y/Y TTM	32.07%	Oper. Margin	-187.50%	RSI (14)	26.56	Volatility	9.85% 8.74%
Employees	838	Debt/Eq	0.07	Sales Y/Y TTM	11070.12%	Profit Margin	-176.49%	Recom	1.85	Target Price	10.70
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	15.22%	Payout	-	Rel Volume	1.42	Prev Close	1.76
Sales Surprise	-40.12%	EPS Surprise	-48.94%	Sales Q/Q	6798.46%	Earnings	May 08 AMC	Avg Volume	12.97M	Price	1.66
SMA20	-42.20%	SMA50	-48.15%	SMA200	-76.81%	Trades		Volume	18,483,407	Change	-5.68%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	UBS	Buy → Neutral	$2
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy	$17
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral	$19 → $10
Nov-20-23	Initiated	Goldman	Buy	$12
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18
May-19-21	Downgrade	Stifel	Buy → Hold
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-03-21	Initiated	Truist	Buy	$50

Show Previous Ratings

May-15-25 05:14AM	Is This Beaten-Down Stock a Buy Near Its 52-Week Low? (Motley Fool)
May-13-25 09:00AM	Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman (PR Newswire) -7.25%
08:53AM	Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-11-25 11:15AM	3 Monster Stocks in the Making (Motley Fool)
May-09-25 07:56PM	Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman (Business Wire) -44.79% +10.29%
11:33AM	Loading…
11:33AM	Iovance Biotherapeutics Stock Sinks 46%. Heres Why the Biotech Is Tumbling. (Barrons.com)
11:03AM	Why Iovance Biotherapeutics Stock Is Crashing Today (Motley Fool)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
03:40AM	Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... (GuruFocus.com)
May-08-25 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:23PM	Iovance Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 (GlobeNewswire)
May-07-25 05:20PM	Iovance Biotherapeutics Q1 2025 Earnings Preview (Seeking Alpha)
May-06-25 08:10AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -11.43%
03:15AM	My 3 Favorite Stocks to Buy Right Now (Motley Fool)
04:01PM	Loading…
May-02-25 04:01PM	Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 (GlobeNewswire) +5.11%
Apr-30-25 05:14AM	2 Beaten-Down Stocks With Incredible Upside Potential (Motley Fool)
Apr-23-25 04:15PM	Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses (GlobeNewswire) +5.33%
06:10AM	Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year. (Motley Fool)
Apr-22-25 07:09AM	Iovance Biotherapeutics: Only For The Brave (Seeking Alpha)
Apr-19-25 10:00AM	This Biotech Stock Could Be the Best Investment of the Decade (Motley Fool)
Apr-18-25 05:44PM	Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts? (Insider Monkey)
05:30PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-25 10:02AM	Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-14-25 10:05AM	Is Iovance Biotherapeutics a Millionaire-Maker? (Motley Fool)
Apr-09-25 09:45AM	Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple (Insider Monkey) +14.74%
Apr-07-25 08:09AM	4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street (Motley Fool)
Apr-03-25 12:07PM	Iovance: Less And Less Likely To Reap Reward From Its Pioneering Work (Seeking Alpha) -8.19%
Mar-28-25 04:30PM	Traws Pharma Announces Management Updates (GlobeNewswire) -6.46%
Mar-25-25 05:43PM	Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? (InsiderMonkey)
01:56PM	Loading…
Mar-22-25 01:56PM	1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street (Motley Fool)
11:05AM	3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not (Motley Fool)
Mar-21-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-17-25 03:46PM	Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? (Insider Monkey)
Mar-12-25 10:15AM	Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? (Motley Fool)
Mar-04-25 07:36AM	Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan (TipRanks)
Feb-28-25 02:37AM	Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ... (GuruFocus.com) -19.49%
Feb-27-25 05:25PM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Iovance Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 (GlobeNewswire)
Feb-21-25 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-20-25 10:01AM	Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-18-25 04:01PM	Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025 (GlobeNewswire)
Feb-12-25 05:30PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-10-25 07:00AM	Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer (GlobeNewswire) -6.50%
Jan-30-25 07:30AM	What's Wrong With Iovance Biotherapeutics Stock? (Motley Fool)
Jan-29-25 08:30AM	Where Will Iovance Biotherapeutics Be in 5 Years? (Motley Fool)
Jan-27-25 04:31AM	Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts (Motley Fool)
Jan-20-25 03:10PM	Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-18-25 06:50PM	3 Stocks That Could Turn $1,000 Into $5,000 by 2030 (Motley Fool)
Jan-17-25 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-25 04:20AM	3 Mid-Cap Stocks That Could Take Off in 2025 (Motley Fool)
Jan-02-25 07:03PM	Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today (Motley Fool) +5.27%
03:24AM	Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing (Insider Monkey)
Dec-20-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-24 04:02AM	If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These (Motley Fool)
Dec-17-24 05:29AM	2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? (Motley Fool)
Dec-12-24 10:00AM	Prediction: This Stock Will Beat the Market in 2025 (Motley Fool) -7.23%
Dec-07-24 11:08AM	3 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
Nov-27-24 06:30AM	Is Iovance Biotherapeutics Stock a Millionaire Maker? (Motley Fool)
Nov-26-24 04:01PM	Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer (GlobeNewswire)
Nov-23-24 11:35AM	Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back (Motley Fool)
10:31AM	Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 10:00AM	2 Innovative Stocks That Could Deliver Outsize Returns (Motley Fool)
07:49AM	Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-08-24 08:03AM	Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com) -13.80%
Nov-07-24 05:45PM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Iovance Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 (GlobeNewswire)
Oct-31-24 04:01PM	Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 (GlobeNewswire) -5.43% +7.18%
Oct-24-24 06:01PM	Why Iovance Biotherapeutics Stock Triumphed on Thursday (Motley Fool) +7.54%
Oct-18-24 11:01AM	State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc (GuruFocus.com)
Oct-16-24 07:15PM	Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? (Insider Monkey) +8.54%
Oct-12-24 12:28PM	Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? (Insider Monkey)
Oct-10-24 10:39AM	Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential? (Insider Monkey)
Oct-09-24 08:03AM	Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA) (Insider Monkey)
Oct-04-24 08:30AM	Is Iovance Biotherapeutics Stock a Buy? (Motley Fool) +7.17%
Sep-26-24 08:15AM	3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow (Motley Fool)
Sep-16-24 06:29AM	3 Things You Need to Know if You Buy Iovance Biotherapeutics Today (Motley Fool) -5.13%
Sep-14-24 05:32PM	Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 09:30AM	This Is the Biggest Risk With Iovance Biotherapeutics Stock (Motley Fool)
Sep-03-24 05:00PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) -6.95%
Sep-02-24 06:15PM	3 Monster Biotech Stocks to Buy Before 2025 (Motley Fool)
Aug-27-24 04:36AM	Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? (Motley Fool)
Aug-16-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.57%
Aug-14-24 07:15AM	This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock (Motley Fool) -5.87%
Aug-09-24 12:23PM	Why Iovance Biotherapeutics Shares Are Soaring Today (Motley Fool) +24.94%
09:27AM	Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View (Zacks)
Aug-08-24 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.32%
04:24PM	Iovance Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 (GlobeNewswire)
Aug-01-24 10:01AM	Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.53%
Jul-31-24 05:31AM	Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? (Motley Fool)
Jul-29-24 06:24PM	Why Iovance Biotherapeutics Stock Stumbled Today (Motley Fool)
04:01PM	Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 (GlobeNewswire)
08:31AM	Heres Why Iovance Biotherapeutics (IOVA) Declined in Q2 (Insider Monkey)
Jul-19-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-24 02:29PM	7 Death Cross Stocks That Could Be Contrarian Buys (InvestorPlace)
Jul-14-24 05:45AM	Is Iovance Biotherapeutics a Millionaire Maker? (Motley Fool)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vogt Frederick G	Interim CEO & General Counsel	May 14 '25	Buy	1.69	25,000	42,250	374,646	May 16 04:05 PM
Puri Raj K.	Chief Regulatory Officer	Mar 14 '25	Option Exercise	0.00	8,334	0	203,761	Mar 18 08:30 PM
Bellemin Jean-Marc	Chief Financial Officer	Mar 03 '25	Option Exercise	0.00	58,590	0	87,938	Mar 05 08:33 PM
BILINSKY IGOR	Chief Operating Officer	Mar 03 '25	Option Exercise	0.00	62,106	0	120,880	Mar 05 08:32 PM
Vogt Frederick G	Interim CEO & General Counsel	Mar 03 '25	Option Exercise	0.00	223,943	0	445,059	Mar 05 08:32 PM
Puri Raj K.	Chief Regulatory Officer	Mar 03 '25	Option Exercise	0.00	59,999	0	215,411	Mar 05 08:31 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Mar 03 '25	Option Exercise	0.00	62,497	0	126,383	Mar 05 08:30 PM
Vogt Frederick G	Interim CEO & General Counsel	Jan 14 '25	Option Exercise	0.00	20,835	0	231,071	Jan 16 06:01 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 14 '25	Option Exercise	0.00	2,813	0	65,464	Jan 16 06:00 PM
BILINSKY IGOR	Chief Operating Officer	Jan 14 '25	Option Exercise	0.00	2,813	0	60,352	Jan 16 05:59 PM
Puri Raj K.	Chief Regulatory Officer	Dec 16 '24	Option Exercise	0.00	8,334	0	159,171	Dec 18 05:15 PM
Vogt Frederick G	Interim CEO & General Counsel	Dec 02 '24	Option Exercise	0.00	10,417	0	214,662	Dec 04 04:31 PM
BILINSKY IGOR	Chief Operating Officer	Dec 02 '24	Option Exercise	0.00	3,516	0	59,323	Dec 04 04:30 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 02 '24	Option Exercise	0.00	3,906	0	64,633	Dec 04 04:30 PM
Maynard Ryan D	Director	Nov 12 '24	Option Exercise	7.45	50,000	372,500	57,500	Nov 14 05:00 PM
Maynard Ryan D	Director	Nov 12 '24	Sale	10.06	50,000	503,000	7,500	Nov 14 05:00 PM
Maynard Ryan D	Director	Nov 12 '24	Proposed Sale	10.06	50,000	503,104		Nov 12 07:11 PM
Vogt Frederick G	Interim CEO & General Counsel	Oct 14 '24	Option Exercise	0.00	20,834	0	213,096	Oct 16 06:33 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Oct 14 '24	Option Exercise	0.00	2,813	0	62,155	Oct 16 06:32 PM
BILINSKY IGOR	Chief Operating Officer	Oct 14 '24	Option Exercise	0.00	2,813	0	57,235	Oct 16 06:30 PM
Vogt Frederick G	Interim CEO & General Counsel	Sep 03 '24	Option Exercise	0.00	57,292	0	212,175	Sep 05 07:56 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Sep 03 '24	Option Exercise	0.00	27,345	0	71,233	Sep 05 07:54 PM
BILINSKY IGOR	Chief Operating Officer	Sep 03 '24	Option Exercise	0.00	26,954	0	66,313	Sep 05 07:53 PM
Bellemin Jean-Marc	Chief Financial Officer	Sep 03 '24	Option Exercise	0.00	23,438	0	41,239	Sep 05 07:52 PM
Vogt Frederick G	Interim CEO & General Counsel	Jul 15 '24	Option Exercise	0.00	20,835	0	168,160	Jul 17 08:01 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jul 15 '24	Option Exercise	0.00	2,813	0	47,299	Jul 17 08:01 PM
BILINSKY IGOR	Chief Operating Officer	Jul 15 '24	Option Exercise	0.00	2,813	0	42,571	Jul 17 08:00 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 03 '24	Option Exercise	0.00	3,906	0	46,468	Jun 05 08:07 PM
BILINSKY IGOR	Chief Operating Officer	Jun 03 '24	Option Exercise	0.00	3,516	0	41,542	Jun 05 08:05 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 03 '24	Option Exercise	0.00	10,417	0	151,751	Jun 05 08:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA

Iovance Biotherapeutics Inc

Upgrade your FINVIZ experience